Overview

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Status:
Active, not recruiting

Trial end date:
2022-08-12

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Upadacitinib